Table 1.

The demographic characteristics of the study population.

Characteristics	HC (n = 40)	AS (pre-treatment) (n = 32)	AS (post-treatment) (n = 32)	p
Male, n (%)	37 (92.5)	29 (90.6)	–	1.000*
Age, year, mean ± SD	27.05 ± 5.64	28.63 ± 7.53	–	0.314*
HLA-B27 positive, n (%)	–	30 (93.8)	–	–
Duration, month, mean ± SD	–	94.28 ± 48.79	–	–
BASDAI, mean ± SD	–	6.85 ± 2.03	3.28 ± 1.70	<0.001
BASFI, mean ± SD	–	4.46 ± 2.22	2.37 ± 2.01	<0.001
ASDAS-CRP, mean ± SD	–	4.36 ± 0.79	1.07 ± 0.73	<0.001
ESR, mm/H, median (IQR)	–	29.5 (12.5–46.5)	5.0 (3.0–10.8)	<0.001
CRP, mg/L, median (IQR)	–	21.1 (12.4–44.0)	2.6 (1.1–9.5)	<0.001

*P-values were calculated with HCs as references. Other p-values were calculated from the comparison between pre- and post-treatment. HC, health control; AS, ankylosing spondylitis; SD, standard deviation; BASDAI, Bath Ankylosing Spondylitis Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IQR, interquartile range.